Francois Nader - Jul 19, 2022 Form 4/A - Amendment Insider Report for Talaris Therapeutics, Inc. (TALS)

Role: Director
Signature: /s/ Mary Kay Fenton, attorney-in-fact
Stock symbol: TALS
Transactions as of: Jul 19, 2022
Transactions value $: $500,020
Form type: 4/A - Amendment
Date filed: 9/13/2022, 04:27 PM
Date Of Original Report: Jul 25, 2022
Previous filing: Jun 13, 2022
Next filing: May 5, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TALS	Common Stock	Purchase	$176K	+50K		$3.52	50K	Jul 19, 2022	Direct	F1
transaction	TALS	Common Stock	Purchase	$188K	+52K	+104%	$3.62	102K	Jul 20, 2022	Direct	F2
transaction	TALS	Common Stock	Other	$0	-248K	-62.78%	$0.00	147K	Jul 21, 2022	By Francois Nader 2020 Trust	F3, F4, F8
transaction	TALS	Common Stock	Other	$0	+248K		$0.00	248K	Jul 21, 2022	By FN TALS LLC	F3, F5
transaction	TALS	Common Stock	Purchase	$136K	+36.5K	+35.78%	$3.72	139K	Jul 21, 2022	Direct	F6
transaction	TALS	Common Stock	Other	$0	-139K	-100%	$0.00^*	0	Jul 25, 2022	Direct	F7
transaction	TALS	Common Stock	Other	$0	+139K	+55.75%	$0.00	387K	Jul 25, 2022	By FN TALS LLC	F5, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.38 to $3.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.51 to $3.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3	Represents the transfer of shares held by the Francois Nader 2020 Trust to FN TALS LLC for no consideration.
F4	These shares are held in a trust for the benefit of the Reporting Person's spouse and child. The Reporting Person''s spouse and child are trustees of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F5	These shares are held by a limited liability company of which the Reporting Person serves as the sole member, with sole voting and investment control over the securities held thereby. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F6	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.595 to $3.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F7	Represents the transfer of shares held by the Reporting Person to FN TALS LLC for no consideration.
F8	This amendment is being filed solely to correct the number of shares reported by the Francois Nader 2020 Trust, which was incorrectly reported due to an administrative error.